Jamie Brinson
Payments from drug & device makers
Across 98 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$420
- Lilly USA, LLC$255
- Novo Nordisk$201
- AstraZeneca$149
- Otsuka America Pharmaceutical, Inc.$115
- GSK$104
- plus $489 from 14 others
What the payments were for
- Food & beverage$1,735100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $420 |
| Lilly USA, LLC | 13 | $255 |
| Novo Nordisk | 16 | $201 |
| AstraZeneca | 7 | $149 |
| Otsuka America Pharmaceutical, Inc. | 5 | $115 |
| GSK | 5 | $104 |
| Tris Pharma Inc | 4 | $85 |
| Bayer | 4 | $68 |
| Pfizer | 3 | $63 |
| Phathom Pharmaceuticals, Inc. | 3 | $52 |
| Amgen | 3 | $43 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Corium, LLC | 1 | $23 |
| Inari Medical, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$118
How this compares
$1,735 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $47,803 |
| JardianceEmpagliflozin | 35 | $27,467 |
| EliquisApixaban | 21 | $22,844 |
| MounjaroTirzepatide | 11 | $11,580 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $9,997 |
| SynthroidLevothyroxine Sodium | 16 | $1,515 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $1,346 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 67 | $942 |
| Levothyroxine Sodium | 93 | $802 |
| Tramadol Hcl | 77 | $701 |
| Losartan Potassium | 53 | $672 |
| Gabapentin | 74 | $648 |
| Ezetimibe | 30 | $630 |
| Atorvastatin Calcium | 38 | $594 |
| Testosterone Cypionate | 12 | $562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $201 | $47,80339 claims |
| Boehringer IngelheimJardiance | $13 | $27,46735 claims |
| PfizerEliquis | $63 | $22,84421 claims |
| Lilly USA, LLCMounjaro | $255 | $11,58011 claims |
| GSKTrelegy Ellipta | $104 | $9,99712 claims |
| AbbVieSynthroid | $420 | $1,51516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.
Other family in Sylva
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.